ESTRO 2024 - Abstract Book

S1031

Clinical - Gynaecology

ESTRO 2024

SUV-max's prognostic value in LACC remains uncertain. Considering post-treatment parameters and other FDG PET indices may provide insights. Achieving adequate irradiation doses and addressing anemia are critical for better LACC outcomes.

Keywords: prognostic factors, SUVmax FDG-PET, LACC

1107

Poster Discussion

Sarcopenic obesity is a key prognostic factor in advanced cervical cancer: an observational study

Federica Medici 1,2 , Paolo Castellucci 3 , Ludovica Forlani 1,2 , Martina Ferioli 1 , Alessandra Arcelli 1,2 , Johnny Ma 1,2 , Viola Laghi 1,2 , Savino Cilla 4 , Milly Buwenge 1 , Gabriella Macchia 5 , Luca Tagliaferri 6 , Anna Myriam Perrone 1,7 , Pierandrea De Iaco 1,7 , Lidia Strigari 8 , Stefano Fanti 9 , Alessio Giuseppe Morganti 1,2 1 Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum University of Bologna, Bologna, Italy. 2 Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. 3 Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. 4 Medical Physics Unit, Gemelli Molise Hospital Università Cattolica del Sacro Cuore, Campobasso, Italy. 5 Radiotherapy Unit, Gemelli Molise Hospital, Fondazione Policlinico Universitario A. Gemelli IRCCS, Campobasso, Italy. 6 UOC di Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy. 7 Division of Gynecologic Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. 8 Medical Physics, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. 9 Nuclear Medicine, Alma Mater Studiorum University of Bologna, Bologna, Italy

Purpose/Objective:

The aim of this study was to explore the prognostic impact of patients' nutritional status, including pre-treatment body mass index (BMI), sarcopenia (SP), and sarcopenic obesity (SO), in locally advanced cervical cancer (LACC). We sought to investigate whether these factors were correlated with disease control and survival outcomes.

Material/Methods:

We conducted an observational study on LACC patients treated at our institution between 2007 and 2021 with concurrent chemoradiation (CRT) and subsequent brachytherapy (BRT) boost (ESTHER study). Patient characteristics, tumor-related parameters, and treatment details were collected. Additionally, nutritional status and body composition indicators, including prognostic nutritional index (PNI), BMI, SP, and SO, were assessed. SP was determined by measuring skeletal muscle area at the third lumbar vertebra using pre-treatment CT scans, and SO was defined when patients with SP had a BMI ≥ 30 kg/m².

Results:

In our cohort of 173 LACC patients with a median follow-up of 36 months, we observed several prognostic correlations (Table 1: univariate analysis; Table 2: multivariable analysis). Advanced age was significantly